{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:22:47Z","timestamp":1770978167743,"version":"3.50.1"},"reference-count":163,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Child and Adolescent Psychiatric Clinics of North America"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1016\/j.chc.2005.06.004","type":"journal-article","created":{"date-parts":[[2005,9,20]],"date-time":"2005-09-20T09:03:55Z","timestamp":1127207035000},"page":"877-908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Psychopharmacologic Treatment of Pediatric Anxiety Disorders"],"prefix":"10.1016","volume":"14","author":[{"given":"Shauna P.","family":"Reinblatt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John T.","family":"Walkup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/archpsyc.1987.01800130081010","article-title":"DSM-III disorders in preadolescent children: prevalence in a large sample from the general population","volume":"44","author":"Anderson","year":"1987","journal-title":"Arch Gen Psychiatry"},{"issue":"10 Suppl","key":"10.1016\/j.chc.2005.06.004_bib2","doi-asserted-by":"crossref","first-page":"69S","DOI":"10.1097\/00004583-199710001-00006","article-title":"Practice parameters for the assessment and treatment of children and adolescents with anxiety disorders","volume":"36","author":"Bernstein","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1056-4993(18)30138-X","article-title":"Pharmacologic treatment of anxiety disorders in children and adolescents","volume":"9","author":"Velosa","year":"2000","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"10.1016\/j.chc.2005.06.004_bib4","series-title":"Anxiety disorders in children and adolescents","first-page":"109","article-title":"Epidemiology","author":"Costello","year":"1995"},{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/archpsyc.55.1.56","article-title":"The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders","volume":"55","author":"Pine","year":"1998","journal-title":"Arch Gen Psychiatry"},{"issue":"10","key":"10.1016\/j.chc.2005.06.004_bib6","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/archpsyc.1985.01790330057007","article-title":"Clomipramine treatment of childhood obsessive-compulsive disorder: a double-blind controlled study","volume":"42","author":"Flament","year":"1985","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00004583-199201000-00008","article-title":"Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder: a multicenter trial","volume":"31","author":"DeVeaugh-Geiss","year":"1992","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"10.1016\/j.chc.2005.06.004_bib8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0924-977X(93)90266-O","article-title":"A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder: the Lilly European OCD Study Group","volume":"3","author":"Montgomery","year":"1993","journal-title":"Eur Neuropsychopharmacol"},{"issue":"7","key":"10.1016\/j.chc.2005.06.004_bib9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/archpsyc.1994.03950070051010","article-title":"A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder","volume":"51","author":"Tollefson","year":"1994","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"10.1016\/j.chc.2005.06.004_bib10","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1097\/01.chi.0000138356.29099.f1","article-title":"Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial","volume":"43","author":"Geller","year":"2004","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"10.1016\/j.chc.2005.06.004_bib11","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00004583-200107000-00011","article-title":"Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial","volume":"40","author":"Geller","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"10.1016\/j.chc.2005.06.004_bib12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00004583-200102000-00017","article-title":"Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial","volume":"40","author":"Riddle","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"10.1016\/j.chc.2005.06.004_bib13","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1097\/00004583-199211000-00011","article-title":"Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder","volume":"31","author":"Riddle","year":"1992","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00004583-199001000-00008","article-title":"Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: preliminary clinical experience","volume":"29","author":"Riddle","year":"1990","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"16","key":"10.1016\/j.chc.2005.06.004_bib15","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1001\/jama.292.16.1969","article-title":"Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial","volume":"292","year":"2004","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.chc.2005.06.004_bib16","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJM200104263441703","article-title":"Fluvoxamine for the treatment of anxiety disorders in children and adolescents","volume":"344","author":"Walkup","year":"2001","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.chc.2005.06.004_bib17","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/01.CHI.0000037049.04952.9F","article-title":"Fluoxetine for the treatment of childhood anxiety disorders","volume":"42","author":"Birmaher","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"12","key":"10.1016\/j.chc.2005.06.004_bib18","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1176\/appi.ajp.158.12.2008","article-title":"Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder","volume":"158","author":"Rynn","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.chc.2005.06.004_bib19","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1176\/ajp.117.12.1088","article-title":"The effectiveness of psychotherapy alone and in conjunction with perphenazine or placebo in the treatment of neurotic and hyperkinetic children","volume":"117","author":"Eisenberg","year":"1961","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.chc.2005.06.004_bib20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1939-0025.1960.tb03018.x","article-title":"The effectiveness of tranquilizing drugs plus supportive psychotherapy in treating behavior disorders of children: a double blind study of eighty outpatients","volume":"30","author":"Cytryn","year":"1960","journal-title":"Am J Orthopsychiatry"},{"issue":"6","key":"10.1016\/j.chc.2005.06.004_bib21","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archpsyc.1971.01750120068012","article-title":"EEG and behavioral effects of drug therapy in children: chlorpromazine and diphenhydramine","volume":"24","author":"Korein","year":"1971","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.chc.2005.06.004_bib22","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/archpsyc.1971.01750150012002","article-title":"Controlled imipramine treatment of school phobia","volume":"25","author":"Gittleman-Klein","year":"1971","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.chc.2005.06.004_bib23","series-title":"Diagnostic and statistical manual of mental disorders","year":"1980"},{"issue":"10","key":"10.1016\/j.chc.2005.06.004_bib24","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/00004583-200010000-00002","article-title":"K-SADS-PL","volume":"39","author":"Kaufman","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00004583-200001000-00014","article-title":"NIMH diagnostic interview schedule for children version IV (NIMH DISC-IV): description, differences from previous versions, and reliability of some common diagnoses","volume":"39","author":"Shaffer","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2005.06.004_bib26","series-title":"Pediatric psychopharmacology: principles and practice","first-page":"496","article-title":"Anxiety disorders","author":"Labellarte","year":"2003"},{"issue":"20","key":"10.1016\/j.chc.2005.06.004_bib27","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1001\/jama.280.20.1752","article-title":"Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial","volume":"280","author":"March","year":"1998","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.chc.2005.06.004_bib28","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/00004583-198811000-00018","article-title":"Obsessive compulsive disorder in adolescence: an epidemiological study","volume":"27","author":"Flament","year":"1988","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"11","key":"10.1016\/j.chc.2005.06.004_bib29","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1097\/00004583-199511000-00008","article-title":"Obsessive-compulsive disorder in a birth cohort of 18-year-olds: prevalence and predictors","volume":"34","author":"Douglass","year":"1995","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib30","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1176\/ajp.152.1.76","article-title":"A family study of obsessive-compulsive disorder","volume":"152","author":"Pauls","year":"1995","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.chc.2005.06.004_bib31","series-title":"Pediatric psychopharmacology: principles and practice","first-page":"511","article-title":"Obsessive-compulsive disorder","author":"Geller","year":"2003"},{"issue":"10","key":"10.1016\/j.chc.2005.06.004_bib32","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0006-3223(02)01677-3","article-title":"The identification of OCD-related subgroups based on comorbidity","volume":"53","author":"Nestadt","year":"2003","journal-title":"Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.chc.2005.06.004_bib33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/da.10058","article-title":"Obsessive-compulsive disorder with and without tics in a clinical sample of children and adolescents","volume":"16","author":"Hanna","year":"2002","journal-title":"Depress Anxiety"},{"issue":"3","key":"10.1016\/j.chc.2005.06.004_bib34","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.mp.4001617","article-title":"Obsessive-compulsive disorder phenotypes: implications for genetic studies","volume":"10","author":"Miguel","year":"2005","journal-title":"Mol Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2005.06.004_bib35","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1056-4993(18)30170-6","article-title":"Cognitive behavioral therapy of childhood OCD","volume":"8","author":"Piacentini","year":"1999","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"4","key":"10.1016\/j.chc.2005.06.004_bib36","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0193-953X(18)30217-X","article-title":"Pharmacologic treatment of obsessive compulsive disorders","volume":"15","author":"Jenike","year":"1992","journal-title":"Psychiatr Clin North Am"},{"issue":"3","key":"10.1016\/j.chc.2005.06.004_bib37","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1469-7610.1990.tb01575.x","article-title":"Childhood obsessive-compulsive disorder: a prospective follow-up study","volume":"31","author":"Flament","year":"1990","journal-title":"J Child Psychol Psychiatry"},{"key":"10.1016\/j.chc.2005.06.004_bib38","series-title":"Child and adolescent clinical psychopharmacology","author":"Green","year":"1997"},{"key":"10.1016\/j.chc.2005.06.004_bib39","series-title":"Psychotropic prescribing guide (PDR)","year":"2004"},{"issue":"11","key":"10.1016\/j.chc.2005.06.004_bib40","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/S0006-3223(99)00248-6","article-title":"The treatment of anxiety disorders in children and adolescents","volume":"46","author":"Labellarte","year":"1999","journal-title":"Biol Psychiatry"},{"issue":"11","key":"10.1016\/j.chc.2005.06.004_bib41","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1176\/appi.ajp.160.11.1919","article-title":"Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder","volume":"160","author":"Geller","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.chc.2005.06.004_bib42","author":"Hammad"},{"issue":"9","key":"10.1016\/j.chc.2005.06.004_bib43","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/01.chi.0000131135.70992.58","article-title":"Selective serotonin reuptake inhibitor-induced sexual dysfunction in adolescents: a review","volume":"43","author":"Scharko","year":"2004","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2005.06.004_bib44","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1089\/cap.2004.14.412","article-title":"Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents","volume":"14","author":"Nilsson","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"7","key":"10.1016\/j.chc.2005.06.004_bib45","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/archpedi.156.7.696","article-title":"Decreased growth during therapy with selective serotonin reuptake inhibitors","volume":"156","author":"Weintrob","year":"2002","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"12","key":"10.1016\/j.chc.2005.06.004_bib46","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1001\/archpsyc.1989.01810120030006","article-title":"Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents: a double-blind crossover comparison","volume":"46","author":"Leonard","year":"1989","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.chc.2005.06.004_bib47","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1089\/104454603322126313","article-title":"Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?","volume":"13","author":"Geller","year":"2003","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"Suppl 4","key":"10.1016\/j.chc.2005.06.004_bib48","first-page":"12","article-title":"The expert consensus guideline series: treatment of obsessive-compulsive disorder","volume":"58","author":"March","year":"1997","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"10.1016\/j.chc.2005.06.004_bib49","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/00004583-200110000-00011","article-title":"Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder","volume":"40","author":"Cook","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2005.06.004_bib50","doi-asserted-by":"crossref","unstructured":"Walkup J.T., Reeve E., Yaryuya-Tobias J., et al. Fluvoxamine for childhood OCD: long-term treatment. Presented at the 45th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Anaheim (CA), October 1998","DOI":"10.1016\/S0924-977X(99)80399-X"},{"issue":"10","key":"10.1016\/j.chc.2005.06.004_bib51","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/archpsyc.1991.01810340054007","article-title":"A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder","volume":"48","author":"Leonard","year":"1991","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"10.1016\/j.chc.2005.06.004_bib52","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.290.8.1033","article-title":"Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials","volume":"290","author":"Wagner","year":"2003","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.chc.2005.06.004_bib53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00004850-199506000-00001","article-title":"A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder","volume":"10","author":"Greist","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.chc.2005.06.004_bib54","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/cap.1997.7.157","article-title":"Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases","volume":"7","author":"Thomsen","year":"1997","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"10","key":"10.1016\/j.chc.2005.06.004_bib55","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/00004583-199810000-00026","article-title":"Summary of the practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder","volume":"37","year":"1998","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib56","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2004.00302.x","article-title":"Long-term outcome of pediatric obsessive-compulsive disorder: a meta-analysis and qualitative review of the literature","volume":"110","author":"Stewart","year":"2004","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"10.1016\/j.chc.2005.06.004_bib57","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/archpsyc.1993.01820180023003","article-title":"A 2- to 7-year follow-up study of 54 obsessive-compulsive children and adolescents","volume":"50","author":"Leonard","year":"1993","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib58","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s007870170045","article-title":"Long-term outcome and prognosis of obsessive-compulsive disorder with onset in childhood or adolescence","volume":"10","author":"Wewetzer","year":"2001","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"5","key":"10.1016\/j.chc.2005.06.004_bib59","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1176\/ajp.152.5.772","article-title":"A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder","volume":"152","author":"McDougle","year":"1995","journal-title":"Am J Psychiatry"},{"issue":"9","key":"10.1016\/j.chc.2005.06.004_bib60","first-page":"423","article-title":"Risperidone in the treatment of affective illness and obsessive-compulsive disorder","volume":"56","author":"Jacobsen","year":"1995","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.chc.2005.06.004_bib61","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/00004583-199407000-00003","article-title":"Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder","volume":"33","author":"Leonard","year":"1994","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib62","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/cap.1998.8.61","article-title":"Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents","volume":"8","author":"Figueroa","year":"1998","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"10.1016\/j.chc.2005.06.004_bib63","first-page":"285","article-title":"Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination","volume":"26","author":"Simeon","year":"1990","journal-title":"Psychopharmacol Bull"},{"issue":"3","key":"10.1016\/j.chc.2005.06.004_bib64","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1017\/S1461145799001546","article-title":"Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study","volume":"2","author":"Fux","year":"1999","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"10.1016\/j.chc.2005.06.004_bib65","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0924-977X(00)00065-1","article-title":"Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial","volume":"10","author":"Dannon","year":"2000","journal-title":"Eur Neuropsychopharmacol"},{"issue":"9","key":"10.1016\/j.chc.2005.06.004_bib66","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/070674378903400902","article-title":"Intravenous chlorimipramine therapy in obsessive-compulsive disorder","volume":"34","author":"Warneke","year":"1989","journal-title":"Can J Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2005.06.004_bib67","first-page":"100","article-title":"Intravenous chlorimipramine in the treatment of obsessional disorder in adolescence: case report","volume":"46","author":"Warneke","year":"1985","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib68","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1176\/jnp.4.1.70","article-title":"Open trial of intravenous clomipramine in five treatment-refractory patients with obsessive-compulsive disorder","volume":"4","author":"Fallon","year":"1992","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"5","key":"10.1016\/j.chc.2005.06.004_bib69","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/archpsyc.1995.03950170058008","article-title":"Cingulotomy for intractable obsessive-compulsive disorder: prospective long-term follow-up of 18 patients","volume":"52","author":"Baer","year":"1995","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"10.1016\/j.chc.2005.06.004_bib70","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1176\/ajp.155.2.264","article-title":"Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases","volume":"155","author":"Swedo","year":"1998","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.chc.2005.06.004_bib71","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1176\/ajp.155.2.264","article-title":"Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases","volume":"155","author":"Swedo","year":"1998","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.chc.2005.06.004_bib72","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1017\/S1461145701002371","article-title":"Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS)","volume":"4","author":"Leonard","year":"2001","journal-title":"Int J Neuropsychopharmacol"},{"issue":"10","key":"10.1016\/j.chc.2005.06.004_bib73","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1097\/00004583-200010000-00020","article-title":"An open trial of plasma exchange in childhood-onset obsessive-compulsive disorder without poststreptococcal exacerbations","volume":"39","author":"Nicolson","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.chc.2005.06.004_bib73b","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1089\/104454603322126377","article-title":"Childhood-onset obsessive-compulsive disorder and tic disorders: case report and literature review","volume":"13","author":"Snider","year":"2003","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"12","key":"10.1016\/j.chc.2005.06.004_bib74","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0006-3223(99)00020-7","article-title":"A pilot study of penicillin prophylaxis for neuropsychiatric exacerbations triggered by streptococcal infections","volume":"45","author":"Garvey","year":"1999","journal-title":"Biol Psychiatry"},{"issue":"7","key":"10.1016\/j.chc.2005.06.004_bib75","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.biopsych.2004.12.035","article-title":"Antibiotic prophylaxis with azithromycin or penicillin for childhood-onset neuropsychiatric disorders","volume":"57","author":"Snider","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib76","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00004583-199201000-00009","article-title":"DSM-III disorders from age 11 to age 15 years","volume":"31","author":"McGee","year":"1992","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2005.06.004_bib77","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1176\/ajp.147.3.313","article-title":"A community study of anxiety in children and adolescents","volume":"147","author":"Kashani","year":"1990","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.chc.2005.06.004_bib78","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0272-7358(94)90012-4","article-title":"Anxiety disorders in adolescence: characteristics, prevalence, and comorbidities","volume":"14","author":"Clark","year":"1994","journal-title":"Clin Psychol Rev"},{"key":"10.1016\/j.chc.2005.06.004_bib79","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJM200104263441703","article-title":"Fluvoxamine for the treatment of anxiety disorders in children and adolescents","volume":"344","year":"2001","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.chc.2005.06.004_bib80","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/00004583-199409000-00009","article-title":"Fluoxetine for childhood anxiety disorders","volume":"33","author":"Birmaher","year":"1994","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2005.06.004_bib81","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/0010-440X(69)90031-5","article-title":"Anxiety attacks with subsequent agoraphobia","volume":"10","author":"Mendel","year":"1969","journal-title":"Compr Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2005.06.004_bib82","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00004583-200003000-00008","article-title":"Imipramine plus cognitive-behavioral therapy in the treatment of school refusal","volume":"39","author":"Bernstein","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib83","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/cap.1997.7.17","article-title":"Open fluoxetine treatment of mixed anxiety disorders in children and adolescents","volume":"7","author":"Fairbanks","year":"1997","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"9","key":"10.1016\/j.chc.2005.06.004_bib84","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/00004583-200209000-00006","article-title":"The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties","volume":"41","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"10.1016\/j.chc.2005.06.004_bib85","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrd1634","article-title":"Depression, antidepressants and suicidality: a critical appraisal","volume":"4","author":"Licinio","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.chc.2005.06.004_bib86","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archpsyc.62.2.165","article-title":"The relationship between antidepressant medication use and rate of suicide","volume":"62","author":"Gibbons","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.chc.2005.06.004_bib90","author":"Elias"},{"issue":"4","key":"10.1016\/j.chc.2005.06.004_bib91","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/0091-3057(88)90209-2","article-title":"Clinical pharmacology of non-benzodiazepine anxiolytics","volume":"29","author":"Lader","year":"1988","journal-title":"Pharmacol Biochem Behav"},{"issue":"8","key":"10.1016\/j.chc.2005.06.004_bib92","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jama.283.8.1025","article-title":"Trends in the prescribing of psychotropic medications to preschoolers","volume":"283","author":"Zito","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.chc.2005.06.004_bib93","series-title":"Pediatric psychopharmacology: principles and practice","first-page":"341","article-title":"Anxiolytics: benzodiazepines, buspirone, and others","author":"Barnett","year":"2003"},{"key":"10.1016\/j.chc.2005.06.004_bib94","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00005053-197303000-00004","article-title":"School phobia: diagnostic considerations in light of imipramine effects","volume":"156","author":"Gittleman-Klein","year":"1973","journal-title":"J Nerv Ment Dis"},{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib95","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00004583-199201000-00005","article-title":"Imipramine treatment of children with separation anxiety disorder","volume":"31","author":"Klein","year":"1992","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"10.1016\/j.chc.2005.06.004_bib96","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00004583-200102000-00015","article-title":"Treatment of school refusal: one-year follow-up","volume":"40","author":"Bernstein","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"10.1016\/j.chc.2005.06.004_bib97","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00004583-199009000-00016","article-title":"Comparative studies of pharmacotherapy for school refusal","volume":"29","author":"Bernstein","year":"1990","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2005.06.004_bib98","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1192\/bjp.138.2.110","article-title":"School phobia: a therapeutic trial with clomipramine and short-term outcome","volume":"138","author":"Berney","year":"1981","journal-title":"Br J Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2005.06.004_bib99","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/00004583-199403000-00011","article-title":"Clonazepam in childhood anxiety disorders","volume":"33","author":"Graae","year":"1994","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib100","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1176\/ajp.140.1.82","article-title":"A controlled clinical trial of alprazolam for the treatment of anxiety","volume":"140","author":"Rickels","year":"1983","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.chc.2005.06.004_bib101","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jama.1983.03340060045024","article-title":"Long-term diazepam therapy and clinical outcome","volume":"250","author":"Rickels","year":"1983","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.chc.2005.06.004_bib102","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archpsyc.1990.01810220015002","article-title":"Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation","volume":"47","author":"Rickels","year":"1990","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib103","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00004583-199201000-00006","article-title":"Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders","volume":"31","author":"Simeon","year":"1992","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"10.1016\/j.chc.2005.06.004_bib104","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1177\/070674378703200712","article-title":"Alprazolam effects in children with anxiety disorders","volume":"32","author":"Simeon","year":"1987","journal-title":"Can J Psychiatry"},{"issue":"5","key":"10.1016\/j.chc.2005.06.004_bib105","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/00004583-199905000-00016","article-title":"Anxiolytics, adrenergic agents, and naltrexone","volume":"38","author":"Riddle","year":"1999","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"10.1016\/j.chc.2005.06.004_bib106","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/00004714-199108000-00016","article-title":"Disinhibition and anger outbursts in adolescents treated with clonazepam","volume":"11","author":"Reiter","year":"1991","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.chc.2005.06.004_bib107","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00004714-198308000-00003","article-title":"Pharmacokinetics of benzodiazepines and psychostimulants in children","volume":"3","author":"Coffey","year":"1983","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.chc.2005.06.004_bib108","first-page":"71","article-title":"Use of anxiolytics in children","volume":"19","author":"Simeon","year":"1993","journal-title":"Encephale"},{"key":"10.1016\/j.chc.2005.06.004_bib109","series-title":"Phobic and anxiety disorders in children and adolescents: a clinician's guide to effective psychosocial and pharmacological interventions","first-page":"306","article-title":"Childhood-onset panic disorder","author":"Birmaher","year":"2004"},{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0193-953X(18)30257-0","article-title":"The pharmacotherapy of anxiety disorders in children and adolescents","volume":"15","author":"Kutcher","year":"1992","journal-title":"Psychiatr Clin North Am"},{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib111","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0193-953X(18)30257-0","article-title":"The pharmacotherapy of anxiety disorders in children and adolescents","volume":"15","author":"Kutcher","year":"1992","journal-title":"Psychiatr Clin North Am"},{"issue":"5","key":"10.1016\/j.chc.2005.06.004_bib112","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4088\/JCP.v62n0508","article-title":"Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial","volume":"62","author":"Pollack","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.chc.2005.06.004_bib113","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1176\/appi.ajp.157.6.968","article-title":"Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder","volume":"157","author":"Rickels","year":"2000","journal-title":"Am J Psychiatry"},{"issue":"23","key":"10.1016\/j.chc.2005.06.004_bib114","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1001\/jama.283.23.3082","article-title":"Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial","volume":"283","author":"Gelenberg","year":"2000","journal-title":"JAMA"},{"issue":"Suppl","key":"10.1016\/j.chc.2005.06.004_bib115","first-page":"51","article-title":"Buspirone in clinical practice","volume":"51","author":"Rickels","year":"1990","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib116","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00004714-199002000-00002","article-title":"Is buspirone effective for panic disorder?","volume":"10","author":"Sheehan","year":"1990","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib117","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0193-953X(18)30257-0","article-title":"The pharmacotherapy of anxiety disorders in children and adolescents","volume":"15","author":"Kutcher","year":"1992","journal-title":"Psychiatr Clin North Am"},{"issue":"3","key":"10.1016\/j.chc.2005.06.004_bib118","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/cap.1997.7.145","article-title":"Buspirone treatment of psychiatrically hospitalized prepubertal children with symptoms of anxiety and moderately severe aggression","volume":"7","author":"Pfeffer","year":"1997","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.chc.2005.06.004_bib119","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/cap.1999.9.73","article-title":"Use of selective serotonin reuptake inhibitors for the treatment of childhood panic disorder: a pilot study","volume":"9","author":"Renaud","year":"1999","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2005.06.004_bib120","series-title":"Practice guidelines for the treatment of psychiatric disorders: compendium 2000","year":"2000"},{"issue":"3","key":"10.1016\/j.chc.2005.06.004_bib121","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1089\/104454602760386888","article-title":"Treating children and adolescents with selective serotonin reuptake inhibitors: how long is appropriate?","volume":"12","author":"Pine","year":"2002","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"11","key":"10.1016\/j.chc.2005.06.004_bib122","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archpsyc.61.11.1153","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder","volume":"61","author":"Wagner","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.chc.2005.06.004_bib123","series-title":"Phobic and anxiety disorders in children and adolescents: a clinician's guide to effective psychosocial and pharmacological interventions","first-page":"433","article-title":"Selective mutism","author":"Garcia","year":"2004"},{"issue":"6","key":"10.1016\/j.chc.2005.06.004_bib124","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/00004583-199211000-00015","article-title":"Elective mutism as a variant of social phobia","volume":"31","author":"Black","year":"1992","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"10.1016\/j.chc.2005.06.004_bib125","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/cap.1999.9.293","article-title":"Sertraline treatment of 5 children diagnosed with selective mutism: a single-case research trial","volume":"9","author":"Carlson","year":"1999","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"7","key":"10.1016\/j.chc.2005.06.004_bib126","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/00004583-199507000-00008","article-title":"Case study: fluoxetine in the multimodal treatment of a preschool child with selective mutism","volume":"34","author":"Wright","year":"1995","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"10.1016\/j.chc.2005.06.004_bib127","first-page":"384","article-title":"Phenelzine treatment of elective mutism: a case report","volume":"51","author":"Golwyn","year":"1990","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.chc.2005.06.004_bib128","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/cap.1999.9.109","article-title":"Phenelzine treatment of selective mutism in four prepubertal children","volume":"9","author":"Golwyn","year":"1999","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.chc.2005.06.004_bib129","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00004583-199605000-00016","article-title":"Fluoxetine treatment of children with selective mutism: an open trial","volume":"35","author":"Dummit","year":"1996","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"10.1016\/j.chc.2005.06.004_bib130","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/00004583-199409000-00010","article-title":"Treatment of elective mutism with fluoxetine: a double-blind, placebo-controlled study","volume":"33","author":"Black","year":"1994","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"10.1016\/j.chc.2005.06.004_bib131","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0887-6185(98)00036-X","article-title":"Resolution of fear of flying with fluoxetine treatment","volume":"12","author":"Abene","year":"1998","journal-title":"J Anxiety Disord"},{"issue":"3","key":"10.1016\/j.chc.2005.06.004_bib132","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0447.1999.tb10852.x","article-title":"Fluvoxamine for phobia of storms","volume":"100","author":"Balon","year":"1999","journal-title":"Acta Psychiatr Scand"},{"issue":"8","key":"10.1016\/j.chc.2005.06.004_bib133","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1176\/ajp.148.8.1090a","article-title":"Treatment of cancer phobia with fluoxetine","volume":"148","author":"Viswanathan","year":"1991","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.chc.2005.06.004_bib134","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s002130000372","article-title":"Double-blind placebo-controlled pilot study of paroxetine for specific phobia","volume":"149","author":"Benjamin","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"10.1016\/j.chc.2005.06.004_bib135","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/104454602760386879","article-title":"Treatment of pediatric anxiety disorders: an open-label extension of the research units on pediatric psychopharmacology anxiety study","volume":"12","author":"Walkup","year":"2002","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"12","key":"10.1016\/j.chc.2005.06.004_bib136","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1176\/ajp.150.12.1779","article-title":"Depressive comorbidity in children and adolescents: empirical, theoretical, and methodological issues","volume":"150","author":"Angold","year":"1993","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.chc.2005.06.004_bib137","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0887-6185(97)00017-0","article-title":"Lifetime comorbidity among anxiety disorders and between anxiety disorders and other mental disorders in adolescents","volume":"11","author":"Lewinsohn","year":"1997","journal-title":"J Anxiety Disord"},{"issue":"12","key":"10.1016\/j.chc.2005.06.004_bib138","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1176\/ajp.151.12.1723","article-title":"Alcohol dependence and anxiety disorders: what is the relationship?","volume":"151","author":"Schuckit","year":"1994","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib139","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00004583-200101000-00024","article-title":"A therapeutic approach to children and adolescents with anxiety disorders and associated comorbid conditions","volume":"40","author":"Manassis","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"10.1016\/j.chc.2005.06.004_bib140","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1176\/ajp.148.5.564","article-title":"Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders","volume":"148","author":"Biederman","year":"1991","journal-title":"Am J Psychiatry"},{"issue":"7","key":"10.1016\/j.chc.2005.06.004_bib141","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/00004583-200107000-00013","article-title":"Comorbidity in childhood anxiety disorders and treatment outcome","volume":"40","author":"Kendall","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"10.1016\/j.chc.2005.06.004_bib142","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00004583-200102000-00009","article-title":"ADHD comorbidity findings from the MTA study: comparing comorbid subgroups","volume":"40","author":"Jensen","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"10.1016\/j.chc.2005.06.004_bib143","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1023\/A:1005179014321","article-title":"Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA)","volume":"28","author":"March","year":"2000","journal-title":"J Abnorm Child Psychol"},{"issue":"7","key":"10.1016\/j.chc.2005.06.004_bib144","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/00004583-200007000-00021","article-title":"The Texas Children's Medication Algorithm Project: Report of the Texas consensus conference panel on medication treatment of childhood attention-deficit\/hyperactivity disorder. Part I. Attention-deficit\/hyperactivity disorder","volume":"39","author":"Pliszka","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"10.1016\/j.chc.2005.06.004_bib145","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1001\/archpedi.155.5.560","article-title":"Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends: 1992 to 1998","volume":"155","author":"Rushton","year":"2001","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"5","key":"10.1016\/j.chc.2005.06.004_bib146","first-page":"762","article-title":"Treatment of ADHD with fluoxetine: a preliminary trial","volume":"30","author":"Barrickman","year":"1991","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"10.1016\/j.chc.2005.06.004_bib147","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/01.chi.0000155320.52322.37","article-title":"Sequential pharmacotherapy for children with comorbid attention-deficit\/hyperactivity and anxiety disorders","volume":"44","author":"Abikoff","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib148","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/(SICI)1520-6394(1999)10:1<18::AID-DA3>3.0.CO;2-R","article-title":"Depression in anxious children: possible factors in comorbidity","volume":"10","author":"Manassis","year":"1999","journal-title":"Depress Anxiety"},{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib149","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00004583-199101000-00007","article-title":"Comorbidity and severity of anxiety and depressive disorders in a clinic sample","volume":"30","author":"Bernstein","year":"1991","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2005.06.004_bib150","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1207\/S15374424JCCP3003_4","article-title":"The prospective relation between dimensions of anxiety and the initiation of adolescent alcohol use","volume":"30","author":"Kaplow","year":"2001","journal-title":"J Clin Child Psychol"},{"issue":"10","key":"10.1016\/j.chc.2005.06.004_bib151","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1097\/00004583-199510000-00023","article-title":"Traumas and posttraumatic stress disorder in a community population of older adolescents","volume":"34","author":"Giaconia","year":"1995","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"11 Suppl","key":"10.1016\/j.chc.2005.06.004_bib152","first-page":"3","article-title":"Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder","volume":"161","author":"Ursano","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"Suppl 16","key":"10.1016\/j.chc.2005.06.004_bib153","first-page":"3","article-title":"The expert consensus guideline series: treatment of posttraumatic stress disorder","volume":"60","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.chc.2005.06.004_bib154","series-title":"Phobic and anxiety disorders in children and adolescents: a clinician's guide to effective psychosocial and pharmacological interventions","first-page":"405","article-title":"Posttraumatic stress disorder","author":"Cohen","year":"2004"},{"issue":"11","key":"10.1016\/j.chc.2005.06.004_bib155","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1001\/archpedi.1988.02150110122036","article-title":"Propranolol treatment for childhood posttraumatic stress disorder, acute type: a pilot study","volume":"142","author":"Famularo","year":"1988","journal-title":"Am J Dis Child"},{"issue":"9","key":"10.1016\/j.chc.2005.06.004_bib156","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1097\/00004583-199609000-00022","article-title":"Clonidine for posttraumatic stress disorder in preschool children","volume":"35","author":"Harmon","year":"1996","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2005.06.004_bib157","series-title":"Catecholamine function in posttraumatic stress disorder: emerging concepts","first-page":"233","article-title":"Neurobiological sequelae of childhood trauma: PTSD in children","author":"Perry","year":"1994"},{"issue":"8","key":"10.1016\/j.chc.2005.06.004_bib157a","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/00004583-199608000-00006","article-title":"Guanfacine for PTSD nightmares","volume":"35","author":"Horrigan","year":"1996","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2005.06.004_bib158","series-title":"Pediatric psychopharmacology: principles and practice","first-page":"580","article-title":"Post-traumatic stress disorder","author":"Donnelly","year":"2003"},{"issue":"1","key":"10.1016\/j.chc.2005.06.004_bib159","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/10445460252943551","article-title":"Comparison of response to a selective serotonin reuptake inhibitor in children, adolescents, and adults with posttraumatic stress disorder","volume":"12","author":"Seedat","year":"2002","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.chc.2005.06.004_bib160","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00004583-199502000-00016","article-title":"Posttraumatic stress disorder in peers of adolescent suicide victims: predisposing factors and phenomenology","volume":"34","author":"Brent","year":"1995","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"8","key":"10.1016\/j.chc.2005.06.004_bib161","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1097\/00004583-200008000-00003","article-title":"Nefazodone for PTSD","volume":"39","author":"Domon","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"10.1016\/j.chc.2005.06.004_bib162","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jama.287.9.1103-JFD20003-3-1","article-title":"From the Food and Drug Administration","volume":"287","author":"Schwetz","year":"2002","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.chc.2005.06.004_bib163","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/00004583-199907000-00018","article-title":"Imipramine treatment in pediatric burn patients with symptoms of acute stress disorder: a pilot study","volume":"38","author":"Robert","year":"1999","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"10.1016\/j.chc.2005.06.004_bib164","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/00004583-199506000-00008","article-title":"Carbamazepine for PTSD","volume":"34","author":"Looff","year":"1995","journal-title":"J Am Acad Child Adolesc Psychiatry"}],"container-title":["Child and Adolescent Psychiatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056499305000623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056499305000623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T22:35:07Z","timestamp":1760999707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056499305000623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":163,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S1056499305000623"],"URL":"https:\/\/doi.org\/10.1016\/j.chc.2005.06.004","relation":{},"ISSN":["1056-4993"],"issn-type":[{"value":"1056-4993","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychopharmacologic Treatment of Pediatric Anxiety Disorders","name":"articletitle","label":"Article Title"},{"value":"Child and Adolescent Psychiatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chc.2005.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}